4.7 Review

Interaction of tumor-associated microglia/macrophages and cancer stem cells in glioma

Related references

Note: Only part of the references are listed.
Article Engineering, Biomedical

Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival

Giuseppina Catania et al.

Summary: The limited efficacy of standard glioblastoma (GBM) treatments is attributed to the highly immunosuppressive characteristics of the tumor microenvironment, interpatient tumor heterogeneity, and physical barriers like the blood brain barrier. In this study, a new local therapy combining doxorubicin (DOX) and CpG was proposed, which exhibited synergistic effects in eradicating GBM. Bioresponsive hyaluronic acid (HA)-drug conjugates were designed for in situ chemoimmunotherapy, with CpG and DOX being conjugated separately to HA. The combined delivery of HA-DOX + HA-CpG showed promising results in a GBM animal model, inducing immune responses, reducing tumor-associated macrophage infiltration, and resulting in long-term survival in a significant percentage of treated animals.

BIOMATERIALS (2023)

Review Medicine, Research & Experimental

Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy

Fatima Khan et al.

Summary: Glioblastoma (GBM) is the most aggressive tumor in the central nervous system and has a highly immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages and microglia (TAMs) are dominant immune cells in the GBM TME and contribute to immunosuppression. Recent progress in single cell technologies allows for precise characterization of TAMs and identification of new TAM subpopulations with specific tumor-modulating functions in GBM. This review discusses TAM heterogeneity and plasticity in the TME and summarizes current potential therapeutic approaches targeting TAMs in GBM. The use of single cell technologies and functional studies is expected to accelerate the development of novel and effective TAM targeted therapeutics for GBM patients.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Immunology

BACH1 as a potential target for immunotherapy in glioblastomas

Feng Yuan et al.

Summary: BACH1 plays an important role in glioblastoma, being closely associated with immune response and potentially serving as a molecular marker for prognosis and immunotherapy response. Overexpression of BACH1 leads to increased production of tumor-associated macrophage (TAM) chemokines and immune checkpoints. Risk and nomogram models based on BACH1 provide reliable assessment tools for prognosis.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Review Oncology

Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment

James L. Gulley et al.

Summary: Transforming growth factor-beta (TGF-beta) and programmed death-ligand 1 (PD-L1) have immunosuppressive functions in the tumor microenvironment (TME) and inhibiting these pathways can improve clinical outcomes and reduce toxicity.

MOLECULAR ONCOLOGY (2022)

Article Oncology

Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors

Arnon Moldrup Knudsen et al.

Summary: Surgical tumor resection induces infiltration of microglia/macrophages and elevated expression of pleiotrophin (PTN) in recurrent glioblastoma tumors, promoting therapeutic resistance and tumor recurrence.

NEURO-ONCOLOGY (2022)

Article Oncology

Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition

Rohit Rao et al.

Summary: This study identified functionally distinct TAM subpopulations in different glioma subtypes, showing varied responses to TAM targeting. Particularly, proneural tumors exhibited significant inhibition with CSF1R inhibition, while mesenchymal tumors showed potential responsiveness to combined anti-angiogenic therapy and CSF1R inhibition.

NEURO-ONCOLOGY (2022)

Article Clinical Neurology

Tumour-associated CD204+ microglia/macrophages accumulate in perivascular and perinecrotic niches and correlate with an interleukin-6-enriched inflammatory profile in glioblastoma

Mia D. Sorensen et al.

Summary: This study is the first to characterize the role of CD204 in the myeloid microenvironment of glioblastoma. The results support the unfavorable prognostic impact of CD204 and suggest that CD204 and interleukin-6 could serve as targets for re-education of TAMs and enhancement of current anti-glioma therapy.

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2022)

Review Pharmacology & Pharmacy

Laser ablation: Heating up the anti-tumor response in the intracranial compartment

Emily C. Lerner et al.

Summary: Immunotherapies have limited success in treating intracranial malignancies due to barriers like BBB and tumor-induced immunosuppression. LITT is an emerging treatment that synergizes with ICI to enhance anti-tumor immune response by disrupting BBB and boosting immune function locally.

ADVANCED DRUG DELIVERY REVIEWS (2022)

Article Oncology

Growth arrest-specific transcript 5 represses endometrial cancer development by promoting antitumor function of tumor-associated macrophages

Jiajie Tu et al.

Summary: The long noncoding RNA growth arrest-specific transcript 5 (GAS5) plays a tumor-suppressor role in tumor-associated macrophages (TAMs) of endometrial cancer (EC). It enhances phagocytosis, activates cytotoxic T cells, inhibits signaling between TAMs and EC cells, promotes M1 polarization, and represses the accumulation and phosphorylation of oncogenic YAP1 in TAMs. These effects inhibit the development of EC.

CANCER SCIENCE (2022)

Article Gastroenterology & Hepatology

GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity

Luis Ruffolo et al.

Summary: Intrahepatic cholangiocarcinoma (iCCA) is characterized by infiltration of suppressive myeloid populations, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). Tumors overexpress granulocyte-macrophage colony-stimulating factor (GM-CSF) which promotes an immunosuppressive microenvironment, but blocking GM-CSF shows promise in promoting anti-tumor immunity and regression.
Article Immunology

Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression

Alan T. Yeo et al.

Summary: Using single-cell transcriptomics and flow cytometry, this study investigated the changes in immune cell composition during the progression of glioblastoma (GBM). The results revealed a transition from pro-inflammatory microglia to infiltrating macrophages and suppressor cells as the tumor advanced.

NATURE IMMUNOLOGY (2022)

Article Oncology

USF1/CD90 signaling in maintaining glioblastoma stem cells and tumor-associated macrophages adhesion

Yuanshuai Zhou et al.

Summary: This study reveals that the USF1/CD90 axis plays a crucial role in promoting malignant growth and stemness of glioblastoma stem cells (GSCs) through physical interaction with tumor-associated macrophages (TAMs). The findings suggest that targeting the USF1/CD90 axis may provide a potential therapeutic strategy for glioblastoma treatment.

NEURO-ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses

Jiajie Tu et al.

Summary: This study explores the potential clinical value and molecular mechanisms of miRNA-22 in tumor cell phagocytosis by macrophages and more efficient T cell priming. miR-22 upregulation enhances the phagocytic ability of macrophages, inhibits glioma cell proliferation and migration, and promotes antigen presentation and efficient T cell priming. The study also identifies HDAC6 as a target and NF-kappa B signaling as a pathway associated with miR-22 in tumor-associated macrophages of glioma.

ONCOGENE (2022)

Review Pharmacology & Pharmacy

Pharmacological targeting of the tumor-immune symbiosis in glioblastoma

Lizhi Pang et al.

Summary: Glioblastoma (GBM) is a common and lethal brain tumor, and the symbiotic interaction between immune cells and GBM cells plays a critical role in tumor progression and therapy resistance. Targeting the tumor-immune symbiosis pharmacologically has emerged as a promising strategy for GBM treatment.

TRENDS IN PHARMACOLOGICAL SCIENCES (2022)

Article Biotechnology & Applied Microbiology

Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma

Jiejian Chen et al.

Summary: The study achieves nuclear targeting of boron by utilizing the nuclear translocation property of doxorubicin, constructing a new nanoliposome delivery system that combines boron neutron capture therapy (BNCT) with immunotherapy, significantly improving the survival rate of tumor-bearing mice.

JOURNAL OF NANOBIOTECHNOLOGY (2022)

Review Immunology

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression

Yunzhou Pu et al.

Summary: This review summarizes the roles and mechanisms of tumor-associated macrophages (TAMs) in the resistance of PD-1/PD-L1 inhibitors. Various therapies, including inhibition of TAM differentiation and re-education of TAM activation, are available to recover the anticancer efficacy of PD-1/PD-L1 inhibitors.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

β2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages

Daqi Li et al.

Summary: The study reveals the tumor-promoting functions of B2M in glioblastoma and suggests potential therapeutic strategies for targeting tumor cells and the immunosuppressive microenvironment. B2M activation leads to the maintenance of stem-like neoplastic populations and induces an anti-inflammatory state, while promoting the polarization of macrophages towards an M2-like phenotype. Inhibition of B2M could attenuate glioblastoma stem cell survival, self-renewal, and tumor growth.

CANCER RESEARCH (2022)

Article Cell Biology

Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy

Chen Chen et al.

Summary: Researchers have developed a cavity-injectable nanoporter-hydrogel superstructure to prevent relapse of glioblastoma multiforme (GBM). This superstructure introduces glioma stem cell-specific chimeric antigen receptor (CAR) genes into macrophages/microglia, stimulating an antitumor immune response and preventing postoperative relapse.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Medicine, Research & Experimental

TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin αvβ5-Src-Stat3 signaling

Peng Peng et al.

Summary: TGFBI, specifically expressed by tumor-associated macrophages (TAMs), plays a role in promoting glioma stem cells (GSCs) maintenance and tumor growth. The exact mechanism involves integrin alpha v beta 5-Src-Stat3 signaling pathway.

THERANOSTICS (2022)

Article Biochemistry & Molecular Biology

Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects

Xiaojun Wang et al.

Summary: The researchers successfully developed M1-like macrophage-derived extracellular vesicles (M1EVs) for the treatment of glioblastoma multiforme (GBM). These M1EVs achieved synergistic immunomodulation, chemiexcited photodynamic therapy (CDT), and hypoxia-activated chemotherapy in GBM, leading to a potent therapeutic effect. The results demonstrated the excellent efficacy of CCA-M1EVs against GBM in cell-derived and patient-derived xenograft models.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Article Oncology

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak et al.

Summary: The study showed that pembrolizumab alone or in combination with bevacizumab had limited efficacy in the treatment of recurrent glioblastoma, failing to improve patient survival rates. Tumor immune biomarkers were not reliable predictors of treatment outcomes, while baseline dexamethasone use and certain tumor biomarkers may impact treatment efficacy.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma

Juri Kiyokawa et al.

Summary: This study demonstrates the immune modulatory impact of ICOVIR17, which mediates HA degradation within the GBM ECM and subsequently modifies the immune landscape of the TME. It offers a mechanistic combination immunotherapy with PD-L1/PD-1 blockade that remodels innate and adaptive immune cells.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

Histopathological investigation of the 1p/19q-codeleted gliomas resected following alkylating agent chemotherapy

Tokunori Kanazawa et al.

Summary: Chemotherapy in 1p/19q-codeleted lower grade gliomas leads to histological changes such as sparse glial background and abundant foamy cell infiltration. The increasing rate of CD68+ cells post-chemotherapy is inversely correlated with patient prognosis, while not with tumor response. Glioma stem cells (GSCs) in conjunction with M2 macrophages are responsible for resistance to and recurrence after alkylating agent chemotherapy in 1p/19q-codeleted gliomas.

JOURNAL OF NEURO-ONCOLOGY (2021)

Article Chemistry, Multidisciplinary

A Virus-Mimicking Nucleic Acid Nanogel Reprograms Microglia and Macrophages for Glioblastoma Therapy

Xihui Gao et al.

Summary: Immunotherapy is a promising approach for treating cancers, but its effectiveness in glioblastoma treatment is limited due to the immunosuppressive tumor microenvironment. A virus-mimicking membrane-coated nucleic acid nanogel, Vir-Gel, has been developed to reprogram microglia and macrophages from a pro-invasive M2 phenotype to an anti-tumor M1 phenotype. This approach significantly enhances the targetability and cell uptake efficiency of therapeutic miRNA, demonstrating improved tumor inhibition efficacy.

ADVANCED MATERIALS (2021)

Article Clinical Neurology

Intraarterial delivery of virotherapy for glioblastoma

Visish M. Srinivasan et al.

Summary: Oncolytic viruses have been used in cancer treatment since the 1990s, with increasing interest in treating glioblastome in recent clinical trials through intraarterial delivery. This review discusses the unique applications of IA delivery of OVs, as well as the synergies with immunotherapy and the potential shortcomings and feasibility of treatment. Future studies may focus on preclinical identification of ideal candidates for translation into clinical trials and further exploration of this novel delivery method.

NEUROSURGICAL FOCUS (2021)

Review Oncology

Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic

Amit Grover et al.

Summary: MDSCs are important regulators of immune responses in cancer, and their association with negative clinical outcomes makes them attractive therapeutic targets. However, the complex nature of MDSC biology presents a substantial challenge for therapeutic targeting. This review discusses the challenges and potential solutions in targeting MDSCs for therapeutic intervention.

CANCER DISCOVERY (2021)

Article Oncology

FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells

Jun Yan et al.

Summary: The study uncovered that in glioma, macrophages promote stem-like phenotypes in cancer cells and immune evasion, showing a close interconnection between the two characteristics in the tumor microenvironment.

CANCER LETTERS (2021)

Review Oncology

Therapeutic Targeting of the Tumor Microenvironment

Leire Bejarano et al.

Summary: This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.

CANCER DISCOVERY (2021)

Review Neurosciences

Macrophages and microglia: the cerberus of glioblastoma

Alice Buonfiglioli et al.

Summary: GBM is a highly aggressive and lethal primary brain tumor, characterized by malignant growth, invasion into brain parenchyma, and resistance to therapy. The GBM microenvironment consists of neoplastic and non-neoplastic cells, with tumor-associated macrophages (TAMs) being the most abundant non-neoplastic cells. TAMs play essential roles in promoting tumor progression by interacting with tumor cells and other non-neoplastic cells in the tumor microenvironment.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2021)

Article Medicine, Research & Experimental

CAR-macrophage: A new immunotherapy candidate against solid tumors

Yizhao Chen et al.

Summary: CAR-M therapy shows potential in targeting solid tumors, but there are limitations that need further research to enhance its therapeutic efficacy.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Article Cell Biology

Up-regulation of miR-6,63a inhibits the cancer stem cell-like properties of glioma via repressing the KDA12A-mediated TGF-β/SMAD signaling pathway

Lei Wang et al.

Summary: miR-663a functions in inhibiting proliferation, migration, invasion, and cancer stem cell-like properties in glioma by targeting KDM2A to reduce the TGF-beta/Smad pathway and decrease the progression of glioma.

CELL CYCLE (2021)

Review Pharmacology & Pharmacy

Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy

Gregory P. Takacs et al.

Summary: Chemokines play a crucial role in regulating cell migration, particularly in the immune system and cancer. Gliomas, as common and challenging primary tumors of the central nervous system, could potentially benefit from immunotherapy approaches. Manipulating chemokine/chemokine receptor systems may offer therapeutic advantages in treating malignant gliomas and other cancers.

PHARMACOLOGY & THERAPEUTICS (2021)

Article Cell Biology

Pro-inflammatory and proliferative microglia drive progression of glioblastoma

Hailong Liu et al.

Summary: Limited understanding of the glioblastoma microenvironment and molecular mechanisms complicates the development of effective treatment strategies. This study unveils the correlation between SETD2 mutation and poor prognosis in IDH-WT adult glioblastoma patients, and identifies a specific subpopulation of high-grade glioma-associated microglia (HGG-AM) with pro-inflammatory and proliferative characteristics that interact with tumor cells to promote progression. The depletion of TGF-beta 1/TbRI significantly reduces HGG-AM density and suppresses tumor growth.

CELL REPORTS (2021)

Article Oncology

Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment

Graham Thomas et al.

Summary: TLR agonists have shown potential as therapeutic targets for cancer immunotherapy by influencing the tumor immune microenvironment. Different TLR agonists have varying effects on immune cell composition, interferon signatures, and expression of immune checkpoint molecules. TLR3 stimulation appears to have unique effects on macrophages, monocytes, and T cells compared to TLR7 and TLR9 agonists, suggesting potential synergies with combination therapy strategies.

FRONTIERS IN ONCOLOGY (2021)

Article Oncology

Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells

Kui Zhail et al.

Summary: The study identified brain-penetrant BACE1 inhibitors as regulators of macrophage-dependent phagocytosis in glioblastoma through IL-6-STAT3 signaling. Utilizing MK-8931 to reprogram pTAMs into sTAMs and promote macrophage phagocytosis, in combination with low-dose radiation, shows promising therapeutic efficacy in suppressing malignant growth in preclinical models. These findings suggest a potential streamline of BACE1 inhibitors for cancer therapy, offering a new approach to enhance macrophage-based therapy for malignant tumors.

NATURE CANCER (2021)

Meeting Abstract Biochemistry & Molecular Biology

CCL2-Dependent Macrophage Recruitment by Glioblastoma Stem Cells: The Role of Gα12 and YAP Signaling

Olga Chaim et al.

FASEB JOURNAL (2021)

Review Oncology

Cancer stem cell-immune cell crosstalk in tumour progression

Defne Bayik et al.

Summary: The development of tumors is affected by cellular heterogeneity and an immunosuppressive tumor microenvironment, which interact with each other and lead to therapeutic resistance. The interaction between cancer stem cells and infiltrating immune cell populations in the tumor microenvironment promotes tumor development and immune evasion.

NATURE REVIEWS CANCER (2021)

Article Oncology

Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells

Dandan Fan et al.

Summary: The study demonstrated that immunosuppressive genes were upregulated in IDH1(WT) glioma patients, and blocking Wnt/beta-catenin signaling improved the hostile immunosuppressive microenvironment, enhancing the treatment efficacy for IDH1(WT) GBM.

ONCOIMMUNOLOGY (2021)

Article Oncology

Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study

Solmaz Sahebjam et al.

Summary: The combination of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab and bevacizumab is generally safe and well tolerated in patients with recurrent high-grade gliomas. In patients without prior bevacizumab treatment, 83% showed complete or partial response, while in bevacizumab-resistant patients, 62% achieved partial response. This treatment approach warrants further investigation for its potential in improving outcomes for high-grade glioma patients.

NEURO-ONCOLOGY (2021)

Article Biochemistry & Molecular Biology

CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model

I-Li Tan et al.

Summary: The immune microenvironment of tumors plays a critical role in tumor progression, with TAMs promoting SHH-MB progression in a mouse model. Inhibiting CSF1R reduces TAMs, prolongs survival, and decreases tumor volume, suggesting therapeutic potential for SHH-MB patients.

ONCOGENE (2021)

Review Immunology

Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity

Filippo Veglia et al.

Summary: MDSCs are pathologically activated cells with potent immunosuppressive activity, closely associated with poor clinical outcomes in diseases like cancer. Recent studies have identified key distinctions between MDSCs and classical neutrophils and monocytes, providing new insights into therapeutic targeting for cancer and autoimmune diseases through understanding their genomic and metabolic characteristics. Emerging data also suggest potential involvement of MDSCs in pregnancy, neonatal biology, and COVID-19.

NATURE REVIEWS IMMUNOLOGY (2021)

Review Immunology

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Kyohei Nakamura et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Article Medicine, Research & Experimental

CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1/2 signaling

Xiang Zhang et al.

LABORATORY INVESTIGATION (2020)

Review Pharmacology & Pharmacy

Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A. Review

Seyed H. Shahcheraghi et al.

CURRENT PHARMACEUTICAL DESIGN (2020)

Article Multidisciplinary Sciences

CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

Joseph A. Flores-Toro et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Review Biochemistry & Molecular Biology

The Roles of miRNA in Glioblastoma Tumor Cell Communication: Diplomatic and Aggressive Negotiations

Andrei Buruiana et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Biochemical Research Methods

Novel ablation methods for treatment of gliomas

Brittanie Partridge et al.

JOURNAL OF NEUROSCIENCE METHODS (2020)

Article Multidisciplinary Sciences

Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity

Christina A. von Roemeling et al.

NATURE COMMUNICATIONS (2020)

Article Multidisciplinary Sciences

Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma

Weiwei Tao et al.

NATURE COMMUNICATIONS (2020)

Review Immunology

Glioblastoma Immune Landscape and the Potential of New Immunotherapies

Thomas Daubon et al.

FRONTIERS IN IMMUNOLOGY (2020)

Review Biochemistry & Molecular Biology

Targeting cancer stem cell pathways for cancer therapy

Liqun Yang et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Review Oncology

Glioblastoma Stem cells: Driving Resilience through Chaos

Briana C. Prager et al.

TRENDS IN CANCER (2020)

Article Biochemistry & Molecular Biology

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Junfei Zhao et al.

NATURE MEDICINE (2019)

Article Multidisciplinary Sciences

Bach1 regulates self-renewal and impedes mesendodermal differentiation of human embryonic stem cells

Xiangxiang Wei et al.

SCIENCE ADVANCES (2019)

Article Biochemistry & Molecular Biology

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

Cyril Neftel et al.

Article Biochemistry & Molecular Biology

ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma

Claire Lailler et al.

BIOSCIENCE REPORTS (2019)

Review Oncology

Molecular targeted therapy of glioblastoma

Emilie Le Rhun et al.

CANCER TREATMENT REVIEWS (2019)

Article Pharmacology & Pharmacy

DNX-2401: an investigational drug for the treatment of recurrent glioblastoma

Brandon Philbrick et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)

Article Multidisciplinary Sciences

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma

Gregor Hutter et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Review Oncology

Checkpoint inhibitors as treatment for malignant gliomas: A long way to the top

Matteo Simonelli et al.

CANCER TREATMENT REVIEWS (2018)

Review Cell Biology

Glioma Stem Cell Niches in Human Glioblastoma Are Periarteriolar

Vashendriya V. V. Hira et al.

JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2018)

Article Oncology

A Spatio-Temporal Model of Macrophage-Mediated Drug Resistance in Glioma Immunotherapy

Yongjiang Zheng et al.

MOLECULAR CANCER THERAPEUTICS (2018)

Review Clinical Neurology

BACE inhibitors in clinical development for the treatment of Alzheimer's disease

Francesco Panza et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2018)

Review Immunology

Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma

Qianquan Ma et al.

FRONTIERS IN IMMUNOLOGY (2018)

Review Cell Biology

Targeting cancer-related inflammation in the era of immunotherapy

Kyohei Nakamura et al.

IMMUNOLOGY AND CELL BIOLOGY (2017)

Article Oncology

Crosstalk between M2 macrophages and glioma stem cells

Leora M. Nusblat et al.

CELLULAR ONCOLOGY (2017)

Article Medicine, Research & Experimental

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

Alexander Scholz et al.

EMBO MOLECULAR MEDICINE (2016)

Article Biochemistry & Molecular Biology

R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling

Daming Cui et al.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2016)

Article Clinical Neurology

Glioma Stem Cells but Not Bulk Glioma Cells Upregulate IL-6 Secretion in Microglia/Brain Macrophages via Toll-like Receptor 4 Signaling

Omar Dildar A. Dzaye et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2016)

Review Biotechnology & Applied Microbiology

Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen

Michael E. Salacz et al.

ONCOTARGETS AND THERAPY (2016)

Article Oncology

JNK1/2 expression and modulation of STAT3 signaling in oral cancer

Ioannis Gkouveris et al.

ONCOLOGY LETTERS (2016)

Article Gastroenterology & Hepatology

Polarized CD163+tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer

Jae-Young Park et al.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2016)

Article Biochemistry & Molecular Biology

WNT1-induced Secreted Protein-1 (WISP1), a Novel Regulator of Bone Turnover and Wnt Signaling

Azusa Maeda et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2015)

Article Biochemistry & Molecular Biology

Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy

B. Auffinger et al.

CELL DEATH AND DIFFERENTIATION (2014)

Review Oncology

Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness

Emmanuel Chautard et al.

JOURNAL OF NEURO-ONCOLOGY (2014)

Article Oncology

Transcriptional diversity of long-term glioblastoma survivors

Naamit K. Gerber et al.

NEURO-ONCOLOGY (2014)

Article Audiology & Speech-Language Pathology

Evaluation of the Internal Structure of Normal and Pathological Guinea Pig Cochleae Using Optical Coherence Tomography

Akinobu Kakigi et al.

AUDIOLOGY AND NEURO-OTOLOGY (2013)

Review Oncology

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Kamal S. Saini et al.

CANCER TREATMENT REVIEWS (2013)

Article Biochemistry & Molecular Biology

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

Stephanie M. Pyonteck et al.

NATURE MEDICINE (2013)

Article Oncology

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy

Xinmei Zhu et al.

JOURNAL OF NEURO-ONCOLOGY (2011)

Article Immunology

Glioma-initiating cells: A predominant role in microglia/macrophages tropism to glioma

Liang Yi et al.

JOURNAL OF NEUROIMMUNOLOGY (2011)

Article Multidisciplinary Sciences

Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells

Masahisa Jinushi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Article Multidisciplinary Sciences

Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages

Florent Ginhoux et al.

SCIENCE (2010)

Review Immunology

Myeloid-derived suppressor cells as regulators of the immune system

Dmitry I. Gabrilovich et al.

NATURE REVIEWS IMMUNOLOGY (2009)

Article Immunology

Astrocytic regulation of human monocytic/microglial activation

Alex M. Kostianovsky et al.

JOURNAL OF IMMUNOLOGY (2008)

Article Oncology

Increased glioma growth in mice depleted of macrophages

Hugo Galarneau et al.

CANCER RESEARCH (2007)

Article Oncology

A perivascular niche for brain tumor stem cells

Christopher Calabrese et al.

CANCER CELL (2007)

Article Cell & Tissue Engineering

Pleiotrophin enhances clonal growth and long-term expansion of human embryonic stem cells

Boon Seng Soh et al.

STEM CELLS (2007)

Article Hematology

Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells

BG Sharifi et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)

Review Medicine, General & Internal

Inflammation and cancer: back to Virchow?

F Balkwill et al.

LANCET (2001)

Article Oncology

Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta

W Wick et al.

JOURNAL OF NEURO-ONCOLOGY (2001)